ATE335501T1 - Mittel zur behandlung von allergischen oder überempfindlichkeitszuständen - Google Patents

Mittel zur behandlung von allergischen oder überempfindlichkeitszuständen

Info

Publication number
ATE335501T1
ATE335501T1 AT99900567T AT99900567T ATE335501T1 AT E335501 T1 ATE335501 T1 AT E335501T1 AT 99900567 T AT99900567 T AT 99900567T AT 99900567 T AT99900567 T AT 99900567T AT E335501 T1 ATE335501 T1 AT E335501T1
Authority
AT
Austria
Prior art keywords
allergic
agents
treatment
hypersensitivity
hypersensitivity conditions
Prior art date
Application number
AT99900567T
Other languages
English (en)
Inventor
Neil Andrew Williams
Timothy Raymond Hirst
John Bienenstock
Original Assignee
Univ Bristol
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Bristol filed Critical Univ Bristol
Application granted granted Critical
Publication of ATE335501T1 publication Critical patent/ATE335501T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
AT99900567T 1998-01-09 1999-01-08 Mittel zur behandlung von allergischen oder überempfindlichkeitszuständen ATE335501T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9800487.2A GB9800487D0 (en) 1998-01-09 1998-01-09 Therapies

Publications (1)

Publication Number Publication Date
ATE335501T1 true ATE335501T1 (de) 2006-09-15

Family

ID=10825085

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99900567T ATE335501T1 (de) 1998-01-09 1999-01-08 Mittel zur behandlung von allergischen oder überempfindlichkeitszuständen

Country Status (14)

Country Link
US (4) US7208155B1 (de)
EP (2) EP1736170A3 (de)
JP (5) JP2002500194A (de)
AT (1) ATE335501T1 (de)
AU (1) AU762478B2 (de)
CA (1) CA2317443C (de)
CY (1) CY1105651T1 (de)
DE (1) DE69932702T2 (de)
DK (1) DK1044014T3 (de)
ES (1) ES2270575T3 (de)
GB (2) GB9800487D0 (de)
NZ (1) NZ526218A (de)
PT (1) PT1044014E (de)
WO (1) WO1999034817A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9800487D0 (en) * 1998-01-09 1998-03-04 Oratol Limited Therapies
DK1964570T3 (da) 2007-03-02 2012-12-17 Protectimmun Gmbh Farmaceutisk sammensætning til beskyttelse mod allergier og inflammatoriske sygdomme
US20120128597A1 (en) * 2008-08-16 2012-05-24 Forschungszentrum Borstel Composition for prevention and treatment of allergic and/or inflammatory diseases
US8241608B2 (en) * 2010-03-23 2012-08-14 Development Center For Biotechnology Treating allergy with detoxified E. coli heat-labile enterotoxin
WO2012049312A1 (en) * 2010-10-15 2012-04-19 Alk-Abelló A/S Suppression of a type 1 hypersensitivity immune response with an unrelated antigen
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US12337025B2 (en) * 2018-05-07 2025-06-24 The Administrators Of The Tulane Educational Fund Mutated e. coli enterotoxins as anti-inflammatory agents
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins
US20220040294A1 (en) * 2020-08-07 2022-02-10 Robert E. Coifman Administration of vaccines to sites of temporally induced cell-mediated hypersensitivity reactions, to facilitate the development of protective sensitization against infectious diseases and cancers

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614611A (en) 1987-12-31 1997-03-25 Tanox Biosystems, Inc. Humanized monoclonal antibodies binding to IgE-bearing B cells but not basophils
WO1991012818A1 (en) 1990-02-23 1991-09-05 Immulogic Pharmaceutical Corporation Superantigen induced immune non-responsiveness
US5681571A (en) * 1993-10-08 1997-10-28 Duotol Ab Immunological tolerance-inducing agent
DE4430041A1 (de) * 1994-08-24 1996-02-29 Milupa Ag Allergieprotektive Formelnahrung
US20010036917A1 (en) * 1995-07-05 2001-11-01 Williams Neil Andrew Therapeutic agents
GB9513733D0 (en) 1995-07-05 1995-09-06 Univ Bristol Therapeutic agents
US5980898A (en) * 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US7097845B2 (en) 1997-04-23 2006-08-29 Jacob Sten Petersen Combinations of antigen and mucosal binding component for inducing specific immunological tolerance
GB9800487D0 (en) * 1998-01-09 1998-03-04 Oratol Limited Therapies
GB9819484D0 (en) * 1998-09-07 1998-10-28 Univ Bristol Therapeutic agents

Also Published As

Publication number Publication date
EP1736170A2 (de) 2006-12-27
GB0014295D0 (en) 2000-08-02
EP1044014A1 (de) 2000-10-18
JP2015166397A (ja) 2015-09-24
ES2270575T3 (es) 2007-04-01
AU762478B2 (en) 2003-06-26
US20150165010A1 (en) 2015-06-18
EP1044014B1 (de) 2006-08-09
US20130345114A1 (en) 2013-12-26
EP1736170A3 (de) 2008-08-20
AU1978299A (en) 1999-07-26
GB9800487D0 (en) 1998-03-04
US8992940B2 (en) 2015-03-31
NZ526218A (en) 2004-10-29
CY1105651T1 (el) 2010-12-22
DE69932702T2 (de) 2007-08-16
PT1044014E (pt) 2006-11-30
US7208155B1 (en) 2007-04-24
CA2317443C (en) 2009-06-09
JP2002500194A (ja) 2002-01-08
JP2009161568A (ja) 2009-07-23
EP1044014B9 (de) 2007-01-03
JP2017081977A (ja) 2017-05-18
WO1999034817A1 (en) 1999-07-15
US20080206284A1 (en) 2008-08-28
DK1044014T3 (da) 2006-11-13
CA2317443A1 (en) 1999-07-15
GB2347625A (en) 2000-09-13
DE69932702D1 (de) 2006-09-21
JP2013151568A (ja) 2013-08-08
US8357372B2 (en) 2013-01-22

Similar Documents

Publication Publication Date Title
ATE186834T1 (de) Verwendung von wirksamen mengen von aktiven stoffen zur behandlung von mischhaut
ATE335501T1 (de) Mittel zur behandlung von allergischen oder überempfindlichkeitszuständen
ATE232082T1 (de) Prophylaktische und therapeutische behandlung von haupt sensibilisierung und -reizung
ATE229502T1 (de) Arylsulfonamide und analoga und ihre verwendung zur behandlung von neurodegenerativen erkrankungen
DE69524682D1 (de) Mittel zur Behandlung von Wunden
EP0801946A3 (de) Verwendung von Salicin als antiirritativer Wirkstoff in kosmetischen und topischen dermatologischen Zubereitungen
ATE62414T1 (de) Mittel zur behandlung von herzerkrankungen.
ATE226014T1 (de) Prophylaktische behandlung der allergischen kontaktdermatitis
DE69631478D1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
DE69116380D1 (de) Pharmazeutische zubereitung zur behandlung verlängerter gerinnungszeit
DE58904683D1 (de) Praeparat mit antikoerperaktivitaet und breitem wirkungsspektrum, daraus bestehende oder diese enthaltende mittel und deren verwendung zur behandlung von bakteriell oder toxin-bedingten erkrankungen und zur bekaempfung von protozoen.
DE68912195D1 (de) Verwendung von Pyrrolicloncarbonsäurealkylestern zur Herstellung eines Arzneimittels zur Behandlung von Ichtyosis.
DE3671365D1 (de) Topische anwendung des 3-phenylacetylamino-2,6-piperidindions zur behandlung von hautfalten und hyperpigmentierung.
ATE222101T1 (de) Verwendung von selegilin oder desmethylselegilin zur behandlung von wunden, verbrennungen und hautschäden
DE59506539D1 (de) Hydrogel für die applikation von therapeutischen und/oder kosmetischen wirkstoffen an die haut
DE69305267D1 (de) Zusammensetzung zur Behandlung von Mastitis und Metritis
ATE182784T1 (de) Hydrogel für die applikation von therapeutischen und/oder kosmetischen wirkstoffen an die haut
EP0945127A3 (de) Verwendung von Acyl-Carnitin
DE59813914D1 (de) Mittel zur behandlung und/oder prophylaxe von mikrozirkulationsstörungen
FI911269A7 (fi) Menetelmä ja koostumus aktiivisten aineiden lisääntyneen pitoisuuden aikaansaamiseksi iholla iontoforeesin avulla
DE69900774D1 (de) Verwendung von topische präparationen mit glyceryl trinitrat und lanolin zur behandlung von erektilen funktionsstörungen
DE69300037D1 (de) Verwendung von Bucillamin zur Herstellung eines Arzneimittels zur Behandlung von Cystinuria.
ATE216884T1 (de) Verwendung von sulbutiamin zur behandlung von psychomotorischen oder psychointellektuellen beschwerden
ATE554787T1 (de) Behandlung von typ-1-diabetes vor und nach der expression von prädispositionsmarkern
DE60043247D1 (de) Verwendung von Peroxidlipiden zur Vorbeugung und/oder Behandlung von irritierenden Effekten eines Wirkstoffes

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1044014

Country of ref document: EP